Hyperviscosity syndromes; hemorheology for physicians and the use of microfluidic devices.
Hyperviscosity syndromes; hemorheology for physicians and the use of microfluidic devices.
复制标题
DOI：
10.1097/moh.0000000000000735
复制
发表时间：
2022-11-01
影响因子：
3.2
通讯作者：
Lam, Wilbur A.
中科院分区：
文献类型：
--
作者：
Musick, Jamie O.;Fibben, Kirby S.;Lam, Wilbur A.
高粘滞综合征可导致显著的发病率和死亡率。测量微循环流变学的现有方法不容易获得，并且在该水平上的相关性和准确性有限。在这篇综述中，我们回顾了选定的高粘滞综合征及其知识的进步，使用微流控平台。粘度在微血管水平急剧变化，因为细胞本身的物理性质成为血流阻力的主要决定因素。目前，过时的粘度测量仅量化全血或血清。血液成分、细胞数量或物理性质本身的变化会导致血液粘度增加。鉴于高粘滞综合征的显著发病率和死亡率，需要并正在开发新的生物物理工具来研究微血管生物物理和血流动力学条件，以帮助预测风险并指导治疗。“芯片实验室”技术的使用继续上升到与护理点，个性化测试和医学的相关性，因为可定制的微流体平台可以独立控制许多体内因素，并且是研究微循环血液流变学的强大工具。
Hyperviscosity syndromes can lead to significant morbidity and mortality. Existing methods to measure microcirculatory rheology are not readily available and limited in relevance and accuracy at this level. In this review, we review selected hyperviscosity syndromes and the advancement of their knowledge using microfluidic platforms. Viscosity changes drastically at the microvascular level as the physical properties of the cells themselves become the major determinants of resistance to blood flow. Current, outdated viscosity measurements only quantify whole blood or serum. Changes in blood composition, cell number, or the physical properties themselves lead to increased blood viscosity. Given the significant morbidity and mortality from hyperviscosity syndromes, new biophysical tools are needed and being developed to study microvascular biophysical and hemodynamic conditions at this microvascular level to help predict those at risk and guide therapeutic treatment. The use of “lab-on-a-chip” technology continues to rise to relevance with point of care, personalized testing and medicine as customizable microfluidic platforms enable independent control of many in vivo factors and are a powerful tool to study microcirculatory hemorheology.
影响因子：
1.4
作者：
Balagopal K;Mathew A;Koshy AG;Jacob JP
通讯作者：
Jacob JP
影响因子：
4.4
作者：
Al-Subaie AM
通讯作者：
Al-Subaie AM